Gasiorek A, Heydorn A, Gabery S, Hjerpsted JB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet 2025;406:135-148.
PMID: 40550229